NCT00063947View on ClinicalTrials.gov

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

February 28, 2009

Conditions
Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

DRUG

gemcitabine hydrochloride

Given IV

RADIATION

radiation therapy

Undergo radiotherapy

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00063947 - Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter